Neurofibromatosis 1 Clinical Trials

16 recruiting

Neurofibromatosis 1 Trials at a Glance

16 actively recruiting trials for neurofibromatosis 1 are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Bethesda, Cincinnati, and Boston. Lead sponsors running neurofibromatosis 1 studies include National Cancer Institute (NCI), Massachusetts General Hospital, and David Miller.

Browse neurofibromatosis 1 trials by phase

Treatments under study

About Neurofibromatosis 1 Clinical Trials

Looking for clinical trials for Neurofibromatosis 1? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neurofibromatosis 1 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neurofibromatosis 1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting

Real-World Treatment Study of Koselugo (Selumetinib)

Neurofibromatosis 1Neurofibroma, Plexiform
AstraZeneca200 enrolled12 locationsNCT06360406
Recruiting
Phase 1Phase 2

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Neurofibromatosis 1
National Cancer Institute (NCI)55 enrolled1 locationNCT04750928
Recruiting

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Neurofibromatosis 1Plexiform Neurofibromas
National Cancer Institute (NCI)476 enrolled6 locationsNCT02544022
Recruiting
Phase 1Phase 2

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Neurofibromatosis 1Leukemia, Juvenile MyelomonocyticJMML+2 more
Therapeutic Advances in Childhood Leukemia Consortium58 enrolled19 locationsNCT05849662
Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 2

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Neurofibromatosis 1Plexiform Neurofibroma
University of Alabama at Birmingham200 enrolled13 locationsNCT06188741
Recruiting
Not Applicable

Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy

Neurofibromatosis 1
Massachusetts General Hospital50 enrolled1 locationNCT07233408
Recruiting
Not Applicable

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

Neurofibromatosis 1Noonan SyndromeCardiofaciocutaneous Syndrome+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05361811
Recruiting

Neurofibromatosis Type 1 Tumor Early Detection Study

Malignant Peripheral Nerve Sheath TumorNeurofibromatosis Type 1Neurofibromatosis 1+4 more
David Miller1,000 enrolled1 locationNCT06515860
Recruiting

RASopathy Biorepository

RAS MutationNeurofibromatosis 1Noonan Syndrome+11 more
Children's Hospital Medical Center, Cincinnati1,000 enrolled1 locationNCT04395495
Recruiting
Not Applicable

A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1

Neurofibromatosis 1
Massachusetts General Hospital294 enrolled1 locationNCT06262113
Recruiting

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Neurofibromatosis 1Nerve Sheath Neoplasms
National Cancer Institute (NCI)225 enrolled1 locationNCT06222203
Recruiting

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

Neuroendocrine NeoplasmParagangliomaPheochromocytoma+23 more
Universidad Nacional Autonoma de Mexico750 enrolled3 locationsNCT06523582
Recruiting

A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)

Neurofibromatosis 1Plexiform Neurofibroma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University2,000 enrolled5 locationsNCT06379230
Recruiting

Neurofibromatosis (NF) Registry Portal

Neurofibromatosis 1Neurofibromatosis 2Schwannomatosis
The Children's Tumor Foundation20,000 enrolled1 locationNCT01885767
Recruiting
Phase 2

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1Plexiform Neurofibromas
Shanghai Kechow Pharma, Inc.70 enrolled1 locationNCT05331105